Cargando…

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box

Cryptosporidiosis causes life-threatening diarrhea in children under the age of 5 years and prolonged diarrhea in immunodeficient people, especially AIDS patients. The standard of care, nitazoxanide, is modestly effective in children and ineffective in immunocompromised individuals. In addition to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jumani, R. S., Bessoff, K., Love, M. S., Miller, P., Stebbins, E. E., Teixeira, J. E., Campbell, M. A., Meyers, M. J., Zambriski, J. A., Nunez, V., Woods, A. K., McNamara, C. W., Huston, C. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913971/ https://www.ncbi.nlm.nih.gov/pubmed/29339392 http://dx.doi.org/10.1128/AAC.01505-17

Ejemplares similares

Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model
por: Stebbins, Erin, et al.
Publicado: (2018)

Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box
por: Jung, Eric H., et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
por: Lunde, Christopher S., et al.
Publicado: (2019)

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis
por: Love, Melissa S., et al.
Publicado: (2017)

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis
por: Baragaña, Beatriz, et al.
Publicado: (2019)

The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
por: Looker, Oliver, et al.
Publicado: (2022)

A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors
por: Jumani, Rajiv S., et al.
Publicado: (2019)

Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites
por: Nugraha, Arifin Budiman, et al.
Publicado: (2019)

Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
por: Nyagwange, James, et al.
Publicado: (2019)

Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
por: Tadele, Markos, et al.
Publicado: (2020)

Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18
por: Paiardini, Alessandro, et al.
Publicado: (2015)

Identification of an Atg8-Atg3 Protein–Protein Interaction Inhibitor from the Medicines for Malaria Venture Malaria Box Active in Blood and Liver Stage Plasmodium falciparum Parasites
por: Hain, Adelaide U.P., et al.
Publicado: (2014)

Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis
por: Hulverson, Matthew A., et al.
Publicado: (2023)

In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica
por: Tadele, Markos, et al.
Publicado: (2021)

Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules
por: Subramanian, Gowtham, et al.
Publicado: (2018)

Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
por: Pasche, Valérian, et al.
Publicado: (2018)

Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box
por: Bhandari, Vasundhra, et al.
Publicado: (2018)

PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion
por: Barnes, Claudia B. G., et al.
Publicado: (2022)

Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
por: Duffy, Sandra, et al.
Publicado: (2017)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

Erratum for Subramanian et al., “Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules”
por: Subramanian, Gowtham, et al.
Publicado: (2019)

Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
por: Wall, Gina, et al.
Publicado: (2019)

Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi
por: Almeida-Paes, Rodrigo, et al.
Publicado: (2021)

Monthly malaria chemoprevention shows potential in an area of very high, perennial malaria transmission
por: Cairns, Matthew, et al.
Publicado: (2015)

Impact of confinement housing on study end-points in the calf model of cryptosporidiosis
por: Graef, Geneva, et al.
Publicado: (2018)

Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
por: Khraiwesh, Mozna, et al.
Publicado: (2016)

Compounds from the Medicines for Malaria Venture Box Inhibit In Vitro Growth of Babesia divergens, a Blood-Borne Parasite of Veterinary and Zoonotic Importance
por: Rizk, Mohamed Abdo, et al.
Publicado: (2021)

Simplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based Drugs
por: Gunsaru, Bornface, et al.
Publicado: (2017)

Notes on Some Remedies. I. Mepacrine in Malaria
por: Chaudhuri, R. N.
Publicado: (1946)

Randomized Comparison of the Efficacies and Tolerabilities of Three Artemisinin-Based Combination Treatments for Children with Acute Plasmodium falciparum Malaria in the Democratic Republic of the Congo
por: Onyamboko, M. A., et al.
Publicado: (2014)

Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria
por: Hien, Tran Tinh, et al.
Publicado: (2017)

Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have In Vitro Activity against Cryptosporidium
por: Bartelt, Luther A., et al.
Publicado: (2018)

Dihydroartemisinin–piperaquine holds promise as an option for malaria prevention in pregnancy
por: Hill, Jenny, et al.
Publicado: (2016)

Emerging treatment options for cryptosporidiosis
por: Love, Melissa S., et al.
Publicado: (2021)

Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei
por: Sykes, Melissa L., et al.
Publicado: (2022)

In vitro Multistage Malaria Transmission Blocking Activity of Selected Malaria Box Compounds
por: Malebo, Hamisi M, et al.
Publicado: (2020)

pfk13-Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom
por: Sutherland, Colin J., et al.
Publicado: (2017)

Factors Associated with Intermittent Preventive Treatment of Malaria During Pregnancy in Mali
por: Diarra, Souleymane S., et al.
Publicado: (2019)

PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites
por: Zeeman, Anne-Marie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mc5dhfkuimmrv2u2irn51ou0ch